AOD-9604 is a synthetic peptide based on the C-terminal region of human growth hormone — the hGH(177-191) fragment with a tyrosine added at one end (Tyr-hGH177-191). Unlike most compounds in this reference set it reached mid-stage human research: studied for obesity through Phase IIb, it was reported to be well tolerated, with a profile indistinguishable from placebo. It was not brought to market as a medicine and is not approved as a medicine anywhere; in the United States it has instead been notified as a food and dietary-supplement ingredient.
By Tessaro Pty Ltd, the maker of Pepti · Last reviewed
This page is a reference, not a protocol. It sets out what the published research reports and whether each finding came from people or from animals, what the absence of a human half-life means for a record, where the compound sits with regulators, and what a clean log holds. It gives no dose figures and no schedule, and the section below explains why that is deliberate.
| Property | Value |
|---|---|
| Class / type | Synthetic peptide; a fragment of human growth hormone (Tyr-hGH177-191), a hexadecapeptide — (Stier et al., 2013; Moré & Kenley, 2014) |
| Evidence base | Human tolerability trials, Phase I to IIb (human), plus lipolysis mechanism studies in obese rats (animal) — (Stier et al., 2013; Ng et al., 2000) |
| Half-life | No reliable human half-life has been published |
| Regulatory status | Not approved as a medicine in any jurisdiction; subject of a United States food-ingredient (GRAS) notification for foods, drinks and dietary supplements (Moré & Kenley, 2014); reviewed by the FDA Pharmacy Compounding Advisory Committee, 2024 |
The human evidence is about tolerability. Across six randomised, double-blind, placebo-controlled trials spanning Phase I to Phase IIb, using intravenous and oral administration in healthy volunteers and obese adults, the published report described a tolerability profile indistinguishable from placebo, with no effect on serum IGF-1 and no adverse effect on carbohydrate metabolism (Stier et al., Journal of Endocrinology and Metabolism, 2013). These are human findings, but they are about tolerability, not a demonstration of weight loss.
The mechanism, and such efficacy signal as exists, is chiefly animal. In obese (Zucker) rats, oral AOD-9604 reduced body-weight gain and increased lipolytic activity in adipose tissue, and — unlike intact growth hormone — did so without an adverse effect on insulin sensitivity (Ng et al., Hormone Research, 2000). The claim that this fragment carries the fat-metabolising action of growth hormone rests on animal and in-vitro work, not a human efficacy result.
The limits follow from the split. A compound can be well tolerated in people and still not earn approval as a medicine, and that is what happened here: AOD-9604 ran through a sizeable human program but was not brought to market as a medicine. Its developer instead pursued it as a food and supplement ingredient, and in the United States it became the subject of a food-ingredient (GRAS) notification for foods, drinks and dietary supplements (Moré & Kenley, 2014). In December 2024 the United States FDA's Pharmacy Compounding Advisory Committee reviewed it (FDA, 2024).
No reliable human half-life has been published. No human pharmacokinetic study has characterised how quickly AOD-9604 is cleared. The preclinical picture is one of very rapid breakdown — work in rat plasma and in dosed pigs describes the peptide being degraded quickly into shorter fragments (Moré & Kenley, 2014) — but an animal or in-vitro figure is not a human figure, and not the number to build a record around.
The practical consequence is the same as for any compound without a settled human clearance curve: you cannot infer where levels sit between entries, so the dated log of what you entered and when is the timeline to rely on. The half-life view for this compound runs entirely on a value you enter; the app does not print a human half-life for AOD-9604, because there is not one.
This is general handling, not product-specific instruction. Peptides degrade by both chemical and physical routes, and are stabilised differently in aqueous solution than in the dried (lyophilized) state (Manning et al., Pharmaceutical Research, 2010): a dried powder is generally the more robust form and is inert until a diluent is added, while solution is more vulnerable and is kept cold and dark, used within a limited window, protected from repeated freeze-thaw, and handled with clean technique. The record-keeping point is the one Pepti cares about — the moment a powder becomes a solution, two facts are created that you will not otherwise remember: the diluent volume you added and the resulting concentration.
Pepti is built for exactly this situation: a compound you already have a figure for, supplied in a form that needs measuring. The reconstitution calculator takes the variables you enter — the vial amount and the diluent volume — and returns the concentration and the draw volume for the figure you hold. Every input is a value you supply; none is a dose the app suggests.
The injection-site rotation tracker keeps a 12-site sequence so each administration lands somewhere other than the last, and the half-life view — because no human half-life exists here — runs entirely on a value you enter. The arithmetic and history are the app's; the clinical figures stay with you.
AOD-9604 is not an approved medicine. Being notified as a food or supplement ingredient is not a medicine label: it comes with no authorised medical dose, no approved titration path, and no clinician-facing guidance for any condition. Any figure published as a “typical dose” for it is therefore not drawn from an approved medical source, because none exists — it comes from forum consensus, vendor copy, or someone extrapolating a number from a study never designed to set one.
Pepti is a measurement and record-keeping tool. It converts a figure you already have into a draw volume and syringe units, tracks what is left in each vial, and remembers where the last injection went — but it does not supply the figure, for this compound or any other. Pages that publish dose tables for compounds like this are publishing folklore with the typography of evidence: the numbers look authoritative because they sit in a table, not because anything stands behind them. The figure belongs to you; the arithmetic is what we are for.
There is no settled medical schedule for this compound, so what makes a record useful is completeness rather than cadence: each entry should say enough that the next one, and your reading of the trend months later, is unambiguous.
The reconstitution calculator converts the figures you already have into a draw volume and a count of doses per vial, and a peptide tracker app keeps those entries, the site sequence and your trend on one timeline.
AOD-9604 is a synthetic peptide based on the C-terminal region of human growth hormone. It is a hexadecapeptide corresponding to the growth-hormone 177-191 fragment with an extra tyrosine added at one end, intended to carry the fat-metabolising action of growth hormone without the rest of the hormone's effects (Stier et al., 2013). It was studied as an investigational candidate for obesity and is not an approved medicine.
No. AOD-9604 is not approved as a medicine by any regulator, in any country, for any indication. It was studied in early- and mid-phase human trials for obesity but was not brought to market as a medicine. In the United States it has been the subject of a food-ingredient notification for use in foods, drinks and dietary supplements, which is a separate pathway from approval as a medicine.
Yes. Six randomised, double-blind, placebo-controlled trials were carried out, spanning Phase I to Phase IIb and using both intravenous and oral administration in healthy and obese adults. Across them the published report described a tolerability profile indistinguishable from placebo, with no effect on serum IGF-1 and no adverse effect on carbohydrate metabolism (Stier et al., 2013). These are tolerability findings; they are not a demonstration of weight-loss benefit.
No reliable human half-life has been published. No human pharmacokinetic study has characterised one. Laboratory and animal work describes very rapid breakdown and clearance, but those are not human figures, and Pepti's half-life tool works from a value you enter yourself rather than one we supply.
No. Pepti supplies no dose figures for AOD-9604 or for anything else. It records the figure you already have from whoever directs your use, converts it into a draw volume and syringe units, tracks what is left in each vial, and keeps the site sequence. The arithmetic is ours; the figure is not.
This page is a reference on published evidence and record-keeping. It does not recommend AOD-9604 or any other substance, and it provides no dose figure, no titration amount, and no schedule. AOD-9604 is not an approved medicine.
The Pepti peptide tracker for iPhone keeps the log, the site sequence, the vial count and the weight trend in one place.
Not medical advice. Pepti is a record-keeping and measurement tool, not a medical device.
Get Pepti on the App Store